Drugs / Thymoglobulin Injectable Product
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03263767 | Jan 2018 → Oct 2021 | graft versus host disease | Nantes University Hospital | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymoglobulin Injectable Product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03263767 ↗ |